Background-Growing evidence suggests that immunotherapy and radiation therapy can be synergistic in the treatment of cancer. We sought to determine the effect of the relative timing and type of immune checkpoint therapy on response of melanoma brain metastases to treatment with stereotactic radiosurgery (SRS).
Introduction
Brain metastases (BrMets) historically develop in 10-40% of all cancer patients with metastatic disease. 1 As survival is increasing in duration with the use of new systemic therapies such as targeted agents and immunotherapies, the incidence of brain metastases is increasing also. 1 Understanding the efficacy of treatments for BrMets and their toxicities is therefore becoming increasingly important. Despite data that shows that both targeted agents and immunotherapy agents can have therapeutic effect in the central nervous system (CNS), 2-4 the long-term control rates for these drugs remain unknown. Because of this, whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and/or surgical resection remain standard treatments for BrMets given their high rate of local treatment success. 5 Radiation therapy, historically thought to be immunosuppressive because of its lymphotoxicity, 6 has more recently been shown to induce pro-inflammatory responses secondary to modulation of antigen presentation and immune signaling pathways. 7 In the setting of systemic use of immune checkpoint inhibitors such as ipilimumab, pembrolizumab, and nivolumab against a variety of tumor types, 8 it remains unknown if combining these agents with standard local treatment modalities might result in synergistic efficacy or toxicity. Given what could be synergistic mechanisms of action between immunotherapy and radiation therapy, it is reasonable to hypothesize that the combination could result in improved treatment outcomes. 9 Further, it is unknown what the best timing might be for achieving maximal synergism, and if anti-CTLA-4 versus anti-PD-1 agents have different interactions with focal therapy.
Because of the increased efficacy of SRS in comparison to fractionated radiation, the majority of melanoma brain metastases at our institution are treated primarily with radiosurgery whenever possible. 10 To explore the possible interaction between immunotherapy and radiation, we therefore performed a retrospective review of our melanoma BrMets patients who received both immune checkpoint therapy and SRS during their disease course, with a focus on how the timing and type of immunotherapy affected lesional response.
Methods

Study design and participants
All patients with melanoma BrMets treated with Gamma Knife stereotactic radiosurgery (SRS) between 2007 and 2015 who also received either anti-CTLA-4 or anti-PD-1 immunotherapy were identified from an IRB-approved institutional database. Patients were excluded if they had leptomeningeal disease or no follow-up imaging after SRS. Individual lesions were also excluded within each patient's data if they were post-operative resection cavities or if the lesions were associated with extensive extralesional hemorrhage. In patients who underwent SRS treatment more than once, each new lesion was studied independently and included in this study.
All patients were treated using the Leksell Perfexion Gamma Knife (Elekta Medical Systems, Inc.). Lesions were treated to a median of 20 Gy (range, 12-24 Gy) to the tumor margin, with doses individualized using institutional standardized modifications of RTOG 90-05, 11 which take into account both tumor volume and number of lesions. Lower doses were prescribed for both increasing tumor volume and increasing number of lesions to be treated. Most patients treated with anti-CTLA-4 therapy received up to four doses of ipilimumab at either 3 mg/kg or 10 mg/kg; several of these patients later received a reinduction course. Patients treated with anti-PD-1 therapy received pembrolizumab, at doses of either of 2 mg/kg or 10 mg/kg every 2 or 3 weeks, or nivolumab, at doses of 3 mg/kg every 2 or 3 weeks. Examination of the number of days elapsed between SRS and either the first or last dose of immunotherapy for each lesion (with lesions treated during immunotherapy assigned a value of 0) demonstrated a cluster of lesions around +/− 4 weeks (Supplemental Figure 1) . On this basis, immunotherapy and radiosurgery treatment to any single lesion was considered concurrent if SRS was administered within 4 weeks of the start or end of immunotherapy; all other lesions were defined as having had non-concurrent treatment.
3D MPRAGE, T1-weighted gadolinium enhanced MR images with 1 mm slice thickness of the whole brain were obtained on the day of SRS treatment and at each follow-up, as described in a previous publication from this institution. 12 To determine lesional response, the maximal diameter of the T1 contrast-enhancing portion of each SRS-treated lesion was measured in three orthogonal planes at the time of treatment and at each follow-up by a single individual, to reduce inter-reader measuring errors. Lesion volumes were calculated using the formula (length × width × height)/2, as previously published. 12 Data collection was censored for any single lesion if it required local intervention, such as surgery, laser thermocoagulation, or salvage radiation or if the patient received bevacizumab therapy. In addition, data collection was also terminated if the patient was switched from anti-CTLA-4 therapy to anti-PD-1 therapy during follow-up or vice versa. Volume changes at each followup were normalized to the baseline treatment volume. For a descriptive graphical analysis of temporal changes in volume, scans were grouped into intervals clustered at 1.5 months, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, and 36 months.
Statistical analysis
Statistical analyses were performed using STATA (Version 13.0, StataCorp, College Station, Texas). Baseline characteristics were compared using chi-square tests (for categoric variables) or ANOVA (for continuous variables). To determine the impact of the relative timing of therapies (concurrent vs non-concurrent) and the type of immunotherapy (anti-CTLA-4 vs anti-PD-1) on early lesional response, we used the Wilcoxon rank-sum test to compare the median percent volume change at follow-up between treatment cohorts at 1.5 months, 3 months, and 6 months, with significance determined by p=0.0167, per the Bonferroni correction for multiple comparisons. These intervals were chosen a priori for clinical relevance and based on our anecdotal experience that differences in treatment response between types of immunotherapy during those months may be most significant. We also used Kaplan-Meier methods to estimate overall survival (OS) per patient, from the time of first SRS treatment, and the log rank test was used to compare median survival between different treatment groups.
Results
Patient demographics
A total of 75 patients with 566 SRS-treated melanoma brain metastases were included in this study. Baseline patient, treatment, and lesion characteristics are listed in Table 1 . The mean age at the time of treatment was 62.5 years, and 68% of the patients were male. Median KPS of the patients was 90 (range 50-100) and median melanoma-specific GPA was 3.0 (range, 0 to 4.0). 81% of the patients had active extra-cerebral metastases at the time of first SRS treatment. Median time from initial diagnosis of primary melanoma to the development of BrMets was 37.5 months (range, 0-318 months). The median lesion size for the entire cohort was 105.6 mm 3 (range, 4-27,482 mm 3 ), and the median marginal dose for each lesion was 20 Gy (range 12-24 Gy). Median length of imaging follow-up per lesion was 6 months (range 1-93 months).
33 patients with 193 lesions had concurrent treatment with immunotherapy and SRS; 9 of these patients had multiple SRS treatments that were all concurrent with immunotherapy. 22 patients with 91 lesions had non-concurrent treatment; 9 of these patients had multiple SRS treatments that were all non-concurrent. The remaining 20 patients with 282 lesions had both concurrent and non-concurrent SRS treatments, with 120 (43%) of these lesions treated concurrently and 162 (57%) of these lesions treated non-concurrently. In total, 313 lesions in 53 patients were treated concurrently, and 253 lesions in 42 patients were treated nonconcurrently. Baseline characteristics for these groups are shown in Table 2 . For the nonconcurrent group, median time between SRS and immunotherapy was 7.3 months (range 1.5-41.6 months), with 195 lesions (77%) receiving immunotherapy before SRS and 58 lesions (23%) receiving immunotherapy after SRS. anti-PD-1 therapy. Baseline characteristics for both groups are shown in Table 3 . While many of the standard demographics were similar between the 2 groups, lesions in the anti-PD-1 group tended to have larger baseline tumor volumes (median of 229.6 mm 3 vs 85.7 mm 3 , p<0.0001), were prescribed lower SRS doses (median of 18 Gy vs 20 Gy, p<0.0001), and were more likely to have concurrent SRS treatment (85% of lesions treated concurrently for anti-PD-1 vs 47% for anti-CTLA-4, p<0.0001).
Early lesional response relative to timing of treatment
As shown in Figure 1a , median percent reduction in lesion volume was significantly greater for the concurrent group than for the non-concurrent group at 1.5 months (−63.1% vs −43.2%, p<0.0001), 3 months (−83.0% vs −52.8%, p<0.0001), and 6 months (−94.9% vs −66.2%, p<0.0001). Because of the differences between the groups in prior treatment with chemotherapy, immunotherapy type, time to development of BrMets from initial melanoma diagnosis, and SRS doses, for sensitivity we analyzed lesions in the subset of 20 patients with both concurrent and non-concurrent SRS treatments, as these patients could serve as their own controls. As expected, there were no longer differences in any baseline characteristics within this subset. Results are shown in Figure 1b where median percent reduction in lesion volume remained significantly greater for the concurrent group than for the non-concurrent group at 1. 
Early lesional response by treatment type
As shown in Figure 2a , median percent reduction in lesion volume was significantly greater for anti-PD-1 than for anti-CTLA-4 at 1.5 months (−71.1% vs −48.2%, p<0.0001), 3 months (−89.3% vs −66.2%, p<0.0001), and 6 months (−95.1% vs −75.9%, p=0.0004). Given the differences in baseline tumor volumes and SRS doses between the two groups, for sensitivity we analyzed a subset of lesions that were 10 mm or larger in diameter and received at least 16 Gy (Figure 2b ). 105 lesions met these criteria, 76 in the anti-CTLA-4 group and 29 in the anti-PD1 group. With subset analysis, median percent reduction in lesion volume remained significantly greater for anti-PD-1 than for anti-CTLA-4 at 1.5 months (−67.4% vs −39.4%, p<0.0001), 3 months (−75.4% vs −48.4%, p=0.0080), and 6 months (−88.4% vs −71.3%, p=0.0154).
We additionally examined if prior therapy with anti-CTLA-4 affected the results for the anti-PD-1 patients. 12 patients with 69 lesions had previously received anti-CTLA-4 whereas 9 patients with 59 lesions were anti-CTLA-4 naïve. There was no consistent difference over time for median percent reduction in lesion volume at 1.5 months (−70.4% vs −72.3%, p=0.68), 3 months (−90.0% vs −78.7% p=0.0088), and 6 months (−92.3% vs −96.6%, p=0.26). 
Combined effect of treatment timing and type on early lesional response
Delayed lesional response
During follow up, 39 lesions in 24 patients demonstrated regrowth to greater than 120% of the baseline volume. Ultimately, 11 lesions in 8 patients required surgical management, with 6 lesions resected and 5 lesions treated with laser thermocoagulation. On pathology, all 11 lesions demonstrated features consistent with radiation necrosis; 3 lesions also contained some viable tumor. There were no significant differences in regrowth incidence when comparing treatment types and relative timing of treatment.
Overall survival
The median OS for all patients from first SRS treatment was 18.5 months (range, 2.1 to 96.1 months) (Figure 3 
Discussion
Little data is available in the literature regarding the effect of timing and type of immune checkpoint therapy on the outcome of patients undergoing radiosurgical treatment of melanoma brain metastases. Our study results suggest that (1) immunotherapy can have a synergistic effect with radiosurgery in the treatment of brain metastases, even in those not known to have PD-L1 expression, and (2) early lesional response is greater and more rapid with concurrent administration of immunotherapy and SRS. Of note, this timing effect remained significant even when we examined a subset of patients who had both concurrent and non-concurrent therapy.
Though much remains unknown about the effect of immunotherapy on brain metastases as well as its interaction with radiation therapy, our findings are consistent with current literature. Preclinical studies have suggested that concurrent treatment is most effective. 7 To date, only a small number of retrospective clinical studies have examined timing in regards to the combination of SRS and immunotherapy for melanoma BrMets. While most of these studies had small patient numbers and failed to identify any significant effect of timing on outcomes, [13] [14] [15] in 2015 Kiess et al. reported in 46 patients that those treated with SRS before or during ipilimumab had increased overall survival compared to those treated with SRS after ipilimumab. 16 They also noted a trend towards higher rates of local control with concurrent treatment when compared to non-concurrent treatment. Schoenfeld et al. also found in a small series of 16 patients that SRS before ipilimumab was associated with increased survival compared to SRS after ipilimumab. 17 Jiang et al. subsequently reported, in abstract form, on a larger cohort of 71 patients that those who received SRS within 5.5 months of their last dose of ipilimumab had significantly improved intracranial control compared to those who received SRS after 5.5 months; however, they did not find a difference in overall survival. 18 While our study was not designed to look at survival, a subanalysis of our data also suggests a trend towards increased survival with concurrent treatment, although this did not reach statistical significance.
Local control rates have reportedly been high for melanoma BrMets treated both with SRS and anti-CTLA-4 therapy as well as SRS and anti-PD-1 therapy. [14] [15] [16] However, to our knowledge no study has attempted to compare anti-PD-1 and anti-CTLA-4 to each other directly in this setting. Our data suggest that, compared to anti-CTLA-4 and SRS, anti-PD-1 and SRS may result in greater and more rapid lesion shrinkage in the initial months after SRS, even after controlling for baseline lesion size and SRS dosing. However, these results may have been influenced by a disproportionate number of lesions in the anti-PD-1 group also having concurrent treatment with SRS. When we examined only lesions that were treated concurrently, the effect of anti-PD-1 on early lesional response was diminished, and remained significant only at the 3 month time point. It is possible however that the lower numbers of lesions and patients in this subgroup resulted in an analysis underpowered to detect smaller differences between anti-PD-1 and anti-CTLA-4.
Limitations of this study include its retrospective nature and relatively low number of patients, particularly in the non-concurrent subset of patients receiving anti-PD-1. Also, while we attempted to address several additional questions in secondary analyses, including the effect of treatment sequence and the effect of prior anti-CTLA-4 use on outcomes for anti-PD-1 and SRS, lower numbers of patients and lesions available for these subgroups may have produced underpowered analyses, obscuring potential differences. In addition, we recognize our use of early lesional response as a surrogate for treatment efficacy has limitations. Although some studies have suggested that significant early lesional response to SRS translates into prolonged local control, 19, 20 ultimately our results still need to be correlated with more traditional measures of clinical outcome. Future studies could also examine treatment response based upon changes in other MR sequences looking at tumor hemorrhage, vascularity and cellularity, or perilesional edema. Finally, given the median survival of 18 months in our study patients, the role that immunotherapy may play in the development of radiation necrosis also needs to be determined.
In conclusion, we find that immune checkpoint therapy administered within 4 weeks of SRS (either prior to or after SRS) results in improved lesional response of melanoma BrMets compared to if immunotherapy and SRS are used more than 4 weeks apart. Anti-PD1 immunotherapy may also have a greater effect on lesional response than anti-CTLA-4 in this setting. While anti-CTLA-4 and anti-PD-1 have distinct mechanisms of action, comparison of monotherapies may become less relevant as oncologists move towards combination therapy. 21 However, the mechanism by which concurrent immunotherapy increases the effect of radiation remains unknown, and it is unclear if this effect is isolated to melanoma or perhaps could be applied to other cancer types that also develop brain metastases. Further testing and validation of these results in larger prospective studies and in other cancer types is warranted. In addition, number of doses of immunotherapy concurrent with radiosurgery needs to be studied to determine if this paradigm could be used to improve the result of other radiotherapy treatments.
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